This study is for people with Systemic Lupus Erythematosus (SLE), a disease where the immune system attacks the body. The study will test a new drug called ianalumab, given with standard treatment, against a placebo (a harmless substance). The study is double-blind, meaning neither the doctors nor the patients will know who gets the real drug. Participants must be at least 12 years old and meet certain health criteria, like having specific antibody levels. People who have taken ianalumab before or have certain infections or health issues cannot join.
- Study Length: The treatment involves monthly injections.
- Visits Needed: Participants must attend regular check-ups.
- Risks: There may be side effects or risks associated with the drug.
If you have SLE and meet the criteria, this study might offer a chance to try a new treatment. However, consider the commitment and potential risks before deciding. Always discuss with your doctor to understand if this study is a good fit for you.